Ongoing Roactemra supply difficulties are set to continue as the European Medicines Agency approves its use for adults with severe COVID-19 who are in receipt of systemic treatment with corticosteroids and requiring supplemental oxygen or mechanical ventilation.
Read more below..
RoActemra (tocilizumab) approved by EMA for use in severe COVID-19